Bavarian Nordic A/S (BAVA.CO) News|
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

24 Jun 2016
Change (% chg)

kr.-10.00 (-4.39%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, Jun 15 2016

BRIEF-Bavarian Nordic: Expansion of IMVAMUNE orders from Canada

* Announces expansion of IMVAMUNE orders from Canadian government

BRIEF-Bavarian Nordic: Positive results from Phase 1 Trial of broad spectrum RSV vaccine

* Announces positive top line results from a Phase 1 Trial of a novel, broad spectrum RSV vaccine in healthy adult and elderly populations

BRIEF-Bavarian Nordic signs $100 million contract for IMVAMUNE in USA

* Announces $100 million supply contract for IMVAMUNE Smallpox Vaccine with the U.S. Government

BRIEF-Bavarian Nordic Q1 EBIT loss increases to DKK 153 million

* Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago

BRIEF-Bavarian Nordic: Positive data for Ebola vaccine regimen

* Said on Tuesday results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events

CORRECTED-BRIEF-Bavarian Nordic to raise up to DKK 665 mln in private placement

* Said on Wednesday resolved to launch an offering of up to 2.8 million shares

BRIEF-Bavarian Nordic FY EBIT decreases to DKK 1.6 million

* FY revenue 1.02 billion Danish crowns versus 1.22 billion crowns year ago

BRIEF-Bavarian Nordic enters research collaboration to develop MRSA vaccine

* Entered into a joint collaboration with Evaxion Biotech and Technical University of Denmark for development of an MVA-BN-based vaccine against MRSA

BRIEF-Bavarian Nordic files registration statement for U.S. ADS IPO

* Bavarian Nordic files registration statement for proposed Initial Public Offering of ADSs in the United States

Select another date: